IRICoR – Finalist for ADRIQ’s Prix Innovation | Sciences de la vie 2016

logo-finaliste_gala2016

From left to right : Mrs. Anne Marinier, Principal Investigator and Director of the Medicinal Chemistry Core Facility at IRIC of the Université de Montréal, Mr. Pascal Monette, President and CEO of the ADRIQ and Mrs. Nadine Beauger, CEO of IRICoR

From left to right : Mrs. Anne Marinier, Principal Investigator and Director of the Medicinal Chemistry Core Facility at IRIC of the Université de Montréal, Mr. Pascal Monette, President and CEO of the ADRIQ and Mrs. Nadine Beauger, CEO of IRICoR

 

Université de Montréal’s Institute for Research in Immunology and Cancer (IRIC) – Commercialization of Research (IRICoR) based at IRIC has been selected as a finalist for the Prix Innovation | Sciences de la vie  2016 organized by the Association pour le développement de la recherche et de l’innovation du Québec (ADRIQ).

This Prix Innovation | Life Science aims at recognizing the performance of a company, group, organization and (or) an individual who significantly contributes to the development of biotechnology, life sciences and technologies health in Quebec.

On October 19, 2016, Nadine Beauger, CEO of IRICoR and Anne Marinier, Principal Investigator and Director of Medicinal Chemistry at Université de Montréal’s IRIC, were awarded IRICoR’s certificate by Pascal Monette, CEO of ADRIQ. (see photo)

 

 

 

The Prix Innovation winners will be announced before some 400 decision-makers of Quebec’s research and innovation ecosystem, at ADRIQ’s 26th Prix Innovation Gala on November 24, 2016 in Montreal. (For more information about the Prix Innovation, click here, only in French)

 

About the Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR)
As Université de Montréal’s cluster of academic research valorization in drug discovery, IRICoR is a not-for-profit organization based at IRIC, with the mandate to accelerate the discovery, development and commercialization of novel therapies in cancer, immunotherapy and related fields.
Since its creation in 2008, IRICoR successfully invests in and supports highly innovative projects to rapidly transition basic research discoveries into innovations geared towards the market, through either partnerships with industry or company creation. For more information about IRICoR: www.iricor.ca

 

About the Institute for Research in Immunology and Cancer (IRIC)
An ultra-modern research hub and training centre located in the heart of the Université de Montreal, IRIC was created in 2003 to shed light on the mechanisms of cancer and discover new, more effective therapies to counter this disease. IRIC operates according to a model that is unique in Canada. Its innovative approach to research has already led to discoveries that will, over the coming years, have a significant impact on the fight against cancer. For more information: www.iric.ca.